Harmony Biosciences Holdings, Inc.HRMYNASDAQ
LOADING
|||
HRMY Revenue Growth (YoY Quarterly)•+28.71%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +16.08% | +19.51% | +19.48% | +16.01% | +28.71% |
| Gross Profit Growth | +11.95% | +17.24% | +20.14% | +15.40% | +25.51% |
| EBITDA Growth | +11.60% | +8.31% | +7.27% | +84.29% | +1.34% |
| Operating Income Growth | -4.34% | +38.64% | +8.09% | +125.60% | +6.12% |
| Net Income Growth | +19.84% | +85.95% | +18.85% | +243.16% | +10.35% |
| EPS Growth | +26.56% | +89.13% | +17.65% | +245.00% | +8.64% |
| EPS Diluted Growth | +25.40% | +88.89% | +16.42% | +240.00% | +10.13% |
| Weighted Average Shares Growth | -5.00% | -2.10% | +0.95% | +1.17% | +2.81% |
| Weighted Average Shares Diluted Growth | -4.25% | -1.08% | +1.61% | +1.54% | +1.06% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +11.73% | -1.44% | +9.14% | +86.14% | +54.23% |
| Free Cash Flow Growth | +11.72% | -1.97% | +8.75% | +88.93% | +54.14% |
| Receivables Growth | +21.17% | +11.99% | +32.93% | +11.81% | +23.50% |
| Inventory Growth | +35.93% | +34.22% | +9.00% | +8.10% | -0.48% |
| Asset Growth | +19.33% | +23.14% | +24.62% | +29.08% | +30.18% |
| Book Value per Share Growth | +30.52% | +44.17% | +38.49% | +41.87% | +36.11% |
| Debt Growth | -7.25% | -7.49% | -8.08% | -8.30% | -8.37% |
| R&D Expense Growth | +45.08% | +14.39% | +55.66% | -21.11% | +116.50% |
| SG&A Expenses Growth | +22.19% | +3.12% | +17.10% | +14.83% | +5.69% |
1 / 4